Page 137 - Advances in Forensic Applications of Mass Spectrometry - Jehuda Yinon

1522_C02.fm Page 120 Wednesday, November 12, 2003 9:36 AM

108. Bodin K. and Svensson J.O. Determination of LSD in urine with liquid
chromatography-mass spectrometry. Ther. Drug Monit. 23, 389, 2001.
109. Nelson C.C. and Foltz R.L. Chromatographic and mass spectrometric meth-
ods for determination of lysergic acid diethylamide (LSD) and metabolites
in body fluids. J. Chromatogr. 580, 97, 1992.
110. Poch G.K., Klette K.L., Hallare D.A., Manglicmot M.G., Czarny R.J.,
McWhorter L.K., and Anderson C.J. The detection of metabolites of LSD in
human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of
LSD. J. Chromatogr. 724, 23, 1999.
111. Poch G.K., Klette K.L., and Anderson C.J. The quantitation of 2-oxo-3-
hydroxy LSD in human urine specimens, a metabolite of LSD: comparative
analysis using liquid chromatography-selected ion monitoring mass spec-
trometry and liquid chromatography-ion trap mass spectrometry. J. Anal.
Toxicol. 24, 170, 2000.
112. Sklerov J.H., Magluilo J., Shannon K.K., and Smith M.L. Liquid chromatog-
raphy-electrospray ionization mass spectrometry for the detection of lyser-
gide and a major metabolite, 2-oxo-3-hydroxy LSD, in urine and blood. J.
Anal. Toxicol. 24, 543, 2000.
113. Canezin J., Cailleux A., Turcant A., Le Bouil A., Harry P., and Allain P.
Determination of LSD and its metabolites in human biological fluids by high-
performance liquid chromatography with electrospray tandem mass spec-
trometry. J. Chromatogr. B 765, 12, 2001.
114. Klette K.L., Horn C.K., Stout P.R., and Anderson C.J. LC-MS analysis of
human urine specimens for 2-oxo-3-hydroxy LSD: method validation for
potential interferants and stability study for 2-oxo-3-hydroxy LSD under
various storage conditions. J. Anal. Toxicol. 26, 193, 2002.
115. Mash D.C., Kovera C.A., Pablo J., Tynale R.F., Evin F.D., Williams E.C.,
Singleton E.G., and Mayor M. Ibogaine complex pharmacokinetics, concerns
for safety, and preliminary efficacy measures. Ann. N.Y. Acad. Sci. 914, 394,
2000.
116. Glick S.D., Maisonneuve I.M., and Szumlinski K.K. 18-methoxycoronaridine
(18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and
mechanism of action. Ann. N.Y. Acad. Sci. 914, 369, 2000.
117. Zhang W., Ramamoorthy Y., Tyndale R.F., Glick S.D., Maisonneuve I.M.,
Kuehne M.E., and Sellers E.M. Metabolism of 18-methoxycoroaridine, an
ibogaine analog, to 18-hydroxycoronaridine by genetically variable
CYP2C219. Drug Metab. Disp. 30, 663, 2002.
118. Forstrom T., Tuominen J., and Karkkainen J. Determination of potentially
hallucinogenic N-dimetylated indoleamines in human urine by HPLC/ESI-
MS-MS. Scand. J. Clin. Lab. Invest. 61, 547, 2001.

© 2004 by CRC Press LLC